Comparing surveyed adults with long COVID and those with just a positive test helps put COVID into perspective

Mary L. Adams, MS, MPH, Joseph Grandpre, PhD, MPH<sup>2</sup>

<sup>1</sup> On Target Health Data LLC, Suffield, CT, USA; madams.ontargethealthdata@gmail.com

<sup>2</sup> Wyoming Department of Health, Cheyenne, WY, USA; joe.grandpre@wyo.gov

Corresponding author: Mary Adams, 247 N Stone St, West Suffield, CT 06093, (860-370-9035).

E-mail: madams.ontargethealthdata@gmail.com

Acknowledgment: This study was partially supported by a cooperative agreement from CDC (#1NU58DP006901) which had no role in the writing of the manuscript.

The authors have no conflicts of interest to disclose.

Word count: Abstract: 277; text: 3,485, words; 3 tables, 1 Supplemental table.

Key words: COVID, long COVID, vaccines, activity limitation, disability, BRFSS

Abstract (277 words)

Introduction: Among adults who test positive for COVID-19, some develop long COVID (symptoms lasting ≥3 months), and some do not. We compared 3 groups on selected measures to help determine strategies to reduce COVID impact.

Methods: Using Stata and data for 385,617 adults from the 2022 Behavioral Risk Factor Surveillance System, we compared adults reporting long COVID, those with just a positive test, and those who never tested positive, on several health status and risk factor measures plus vaccination rates (data for 178,949 adults in 29 states).

Results: Prevalence of just COVID was 26.5% (95% CI 26.2-26.8) and long COVID was 7.4% (7.3-7.6). Compared with adults with just COVID those with long COVID had worse rates for 13 of 17 measures of chronic disease, disability, and poor health status, while those with just COVID had the best results for 15 of the 17 measures among all 3 groups. The 5 risk factors (obesity, diabetes, asthma, cardiovascular disease, and COPD) previously associated with COVID deaths, increased long COVID but not just COVID rates, which were highest among younger and higher income adults. Adults with long COVID had the highest rate among the 3 groups for any COVID risk factors and data from 29 states showed they had the lowest rates for ≥3 vaccine doses of 35.6%, vs. 42.7% and 50.3% for those with just a positive test, and neither, respectively. Vaccination with ≥3 vaccines vs. <3 reduced long COVID rates by 38%, and just COVID rates by 16%.

Conclusions: Results show the seriousness of long COVID vs. just a positive test and that increasing vaccine coverage by targeting adults with risk factors shows promise for reducing COVID impact.

#### Introduction

Some adults who test positive for COVID-19 develop long COVID while most do not. Long Covid can cause a wide range of ongoing symptoms in people who once had COVID-19 and can be considered a disability under the Americans with Disabilities Act [1]. The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing state-based telephone survey of randomly selected non-institutionalized adults that collects data on a range of health topics [2]. Results from the 2022 BRFSS on the prevalence of ever having a positive test for COVID have been reported for all participating states and territories [3] and limited to the 50 states and DC [4] with both studies finding a rate of 34.4%. Only the study based on the 50 states [4] reported a rate for long COVID using the definition of symptoms lasting ≥3 months as a percentage of all adults; that rate was 7.4% (95% CI 7.3-7.6). The other study reported long COVID as a percentage of adults with a positive test, which was 21.8% [3]. This study was undertaken to learn more about the similarities and differences between adults with long COVID and those with just a positive test and those never testing positive. The BRFSS provides an opportunity to compare rates with other survey measures of disability, health status, chronic diseases, health care access, and risk factors to help put the potential burden of COVID and long COVID into perspective. Because most data are available for all 50 states, regional and state differences could be considered. The 2022 BRFSS also included optional questions on COVID vaccinations that could provide potentially useful information for 29 states.

Our main study objective was to compare adults with long COVID (symptoms lasting ≥3 months), those having a positive test that did not develop into long COVID (just COVID), and those never testing positive, on a broad range of disability and health status measures. Our second objective was to determine vaccination rates and approximate effectiveness of vaccines on reducing rates of long COVID and just COVID using data from the 29 states that included optional questions on COVID vaccinations.

#### Methods

BRFSS data are publicly available from all 50 states and DC along with survey questions and information needed for analysis on the Centers for Disease Control and Prevention (CDC) website [5]. Data were already weighted to adjust for the probability of selection and to reflect the adult population of each state by age group, race/ethnicity, education level, marital status, and home ownership. The median response rate for the 50 states plus DC for land line and cell phone surveys combined was 45.1% [5], ranging from 36.2% to 66.8%. A total of 385,617 respondents were included in most analysis with state N's ranging from 3,188 in NV to 26,152 in WA and a median N of 7,473.

Measures: Long COVID was defined as ever testing positive for COVID and reporting symptoms lasting 3 months or longer. Those testing positive without long COVID were considered to have just COVID. Respondents with long COVID were asked about the primary symptom they experienced, with a list read that included "no long-term symptoms that limited your activities." Other measures included age, race/ethnicity, gender, income, education, children in the household, health insurance, employment, disability status (difficulty with hearing, seeing, cognition, walking, dressing, or doing errands alone), frequent (≥14) days of activity limitation in past month (FAL), frequent poor mental health days (FMD), fair or poor general health vs good or better, a depression diagnosis, census region (Northeast, Midwest, South and West), blue vs. red states based on voting in the 2020 Presidential election, current smoking, ecigarette use, and any HIV risk factor in past year (injected drug use, STD treatment, or exchanging sex for money or drugs, had anal sex without a condom, or had four or more sex partners)[4, 5]. A composite measure of 5 chronic conditions (obesity, asthma, cardiovascular disease (CVD), diabetes, and Chronic Obstructive Pulmonary Disease (COPD) among 6 found to be associated with US hospitalizations for COVID [6,7] was included. Data on hypertension, the 6<sup>th</sup> chronic condition, was not available for 2022.

Analysis: Stata version 18.0 (StataCorp LLC, College Station TX) was used to account for the complex sample design of the BRFSS in unadjusted analysis and controlled for the listed factors in multiple logistic regression. The survey measures used to describe the survey design were \_psu and \_ststr, weight=\_llcpwt; linearized variance estimation was selected, and for strata with a single sampling unit, center at the grand mean. Missing values (responses of "don't know" or refusals) for any measure except income were excluded from analysis. Separate univariate analysis was done for just COVID and long COVID (Table 1) to determine the prevalence rates of each for different groups and to help select variables to be included in logistic regression models. Measures with adjusted odds ratios (AORs) having P values >0.05 were removed and only the final logistic regression models are reported. A 3-level measure with the mutually exclusive categories of just COVID, long COVID, and neither was used to compare the groups on a range of health and disability measures (Table 3). Those results compare the rates of the various health measures for adults in each of the 3 groups.

Analysis of vaccination data from 29 states: Optional data on receipt of COVID vaccines were available [5] from a total of 29 states which included 5 states that asked the questions on different survey versions. Data from all survey versions were combined and re-weighted as described [5] under Complex Sampling Weights and Preparing Module Data for Analysis. The 29 states are: AR, CT, DE, GA, HI, ID, IL, IA, KS, LA, ME, MD, MA, MT, NE, NH, NJ, NM, NY, NC, ND, OK, RI, SC, TN, TX, WV, WI, and WY; 14 are blue states (N=100,179) and 15 are red states (N=102,023). Vaccine measures included receipt of any COVID vaccine, number of doses, and ≥3 doses vs <3 for 178,949 respondents.

### Results

As published earlier [4], 34.4% of respondents reported ever having a positive test for COVID, which included the new result of 26.5% (95% CI 26.2-26.8) with just COVID, ranging from 19.2% in OR to 30.9% in MS (Table 1). With 2,897 (0.75%) missing responses removed, 7.4% (7.3-7.6) had long COVID with rates ranging across states from 4.4% in DC to 11.1% in WV

(Table 1). Results for the primary symptom experienced for long COVID were reported earlier [3, 4] with only 5.1% of adults with long COVID reporting no long-term symptoms that limited their activities [4]. Higher rates for just COVID (>30%) were found for ages 18-44 years, income ≥\$75,000, adults with children in the household, current e-cigarette users, and reporting HIV risk (Table 1). Higher rates for long COVID were reported by these same groups except higher income, plus Hispanics and those with any of the 5 chronic conditions associated with COVID morbidity (obesity, asthma, CVD, diabetes, and COPD) [6,7] reported by 49.1% of all adults. Among adults with none of the 5 conditions, 5.7% reported long COVID compared with 12.1% of those with ≥3. Results for both outcomes were confirmed by logistic regression using models including all the measures shown (Table 2). With just COVID as the outcome the highest AOR was 2.01 for age 18-24 vs. age 65+ while the highest AOR for long COVID was 2.94 for respondents with ≥3 of the 5 chronic conditions vs. none. Results of comparisons using the 3-level measure found that that those with just a positive test had the best results for 15 of the 17 measures of chronic disease, disability, and health status among the 3 groups (Table 3), while those with long COVID had the worst results for 13 of the 17 measures.

## Vaccinations

Vaccination data from the 29 states showed that associations with COVID outcomes were similar for adults with 0, 1, or 2 vaccines as were results for 3 or 4+ vaccines so the measure of  $\geq$ 3 vaccine doses vs <3 was chosen for most analyses. Among adults age 65+, 67.8% reported  $\geq$ 3 vaccines compared with 40.4% for adults 18-64 years and 46.9% for all respondents with non-missing age. For all adults, those with long COVID were the least likely of the 3 COVID groups to report  $\geq$ 3 vaccines; 35.6% for adults with long COVID, 42.7% for just a positive test, 50.3% for those never testing positive and 47.1% overall. Long COVID rates were slightly (but not significantly) higher in the 29 states vs. all 50 at 7.5% (7.3-7.8) and  $\geq$ 3 vaccinations appeared to reduce long COVID rates by 38% (from 9.2% to 5.7%) and just COVID rates by 16.2% (from 29.0% to 24.3%). Apparent effectiveness of  $\geq$ 3 vaccines was

confirmed in logistic regression with AORs of 0.66 for long COVID and 0.77 for just COVID (Table S-1).

Results for all 50 states (Tables 1 & 2) showed that red states had significantly higher long COVID rates and AORs than blue states while red and blue states had similar rates for just COVID. Census regions and red/blue states overlapped to some extent: >70% of states in the Northeast or West were blue states while >70% of states in the Midwest or South were red states (not shown). Significant differences between red and blue states were also found for 4 of the 5 risk factors: diabetes (13.0% in red states vs. 11.3% in blue states), obesity (35.8% vs. 31.4%), CVD (10.2% vs. 8.5%), and COPD (7.9% vs. 6.0%), but not asthma The percentage reporting  $\geq$ 3 COVID vaccines from the 29 states was also different for red (40.1%) vs. blue states (53.3%). Apparent vaccine effectiveness of  $\geq$ 3 vs. <3 vaccines at reducing long COVID rates was similar in red and blue states at 35% in red states (reduction of rate from 9.9% to 6.4%) and 37% in blue states (from 8.4% to 5.3%).

# Discussion

This study used 2022 population-based data to compare adults with long COVID, those with just a positive test, and neither, finding that adults who reported just COVID were very different from adults reporting long COVID and rates varied widely across states. Those with just COVID had the lowest (best) rates for 15 of 17 separate measures of chronic conditions, disability, and health status among the 3 groups being compared (Table 3) while adults with long COVID had the worst rates for 13 of those same 17 measures. Risk factor results were also quite different for just COVID and long COVID. In unadjusted and adjusted results, increasing numbers of the risk factors of obesity, diabetes, COPD, CVD, and asthma identified earlier [6,7] increased rates of long COVID from 5.7% for zero risk factors to 12.2% for 3 or more, with  $\geq$ 3 risk factors having the highest AOR of 2.93. For just COVID, unadjusted results in Table 1 showed an inverse association with increasing numbers of the 5 risk factors from a rate of 27.7% for 0 risk factors down to 22.0% for  $\geq$ 3, while adjusted results found younger age and higher income had highest AORs. Because both long COVID and just COVID were more prevalent

among younger adults, 86.3% of adults with long COVID and 83.8% of those with just a positive test were ages 18-64 years. Long COVID, but not just COVID, had significantly higher rates in red vs. blue states which remained when results were controlled for all the measures included in logistic regression. Vaccine results, although limited because only 29 states provided data, showed that ≥3 vaccines reduced long COVID rates by 38% vs. 16.2 % for just a positive test. The role of obesity in COVID risk appears to remain when the outcome is either long COVID or just COVID instead of deaths [8], as seen in Tables 1 and 2. In addition to being a risk factor for COVID complications, obesity has been shown to have a negative impact on immune response [9,10].

Remembering pandemic history might help to put COVID and long COVID in perspective. Before vaccines were available, hospitals and health care workers were overwhelmed and death rates, especially among older adults were high. The situation has changed since vaccines became available in 2021, but the total number of US deaths had reached over one million by the end of 2022 [11]. Results from this study indicate that 34.4% of adults surveyed in 2022 reported they had ever had a positive test, representing 89.8 million of the 261 million adults. Therefore, a rough estimate of case fatality rate (deaths/cases) is about 1%. Those deaths include 415,399 COVID deaths in 2021 and 244,986 deaths in 2022 [12] indicating that COVID deaths are decreasing over time. Long COVID was reported by one-fifth of all respondents reporting a positive test, with a wide range across states, or an estimated 19.3 million adults, and about 69.2 million had only a positive test. While not necessarily fatal (we can't tell from these data), long COVID appears to be serious and chronic (by definition, lasting ≥3 months). Among adults with long COVID in this study, 95% reported symptoms which limited their activities. As of 2022, there were an estimated 69.2 million adults with just a positive COVID test that did not develop into long COVID, but these adults were more likely to report better health status compared with other survey respondents.

How can the above information be used to reduce future impact of COVID and especially long COVID? The decrease in deaths between 2021 and 2022 is likely related to increased immunity to COVID from a combination of natural immunity from the approximately 90 million adults who reported a positive test and from vaccines. Higher vaccination rates among adults 65+ may help account for their lower rates of long COVID and just a positive test compared with younger adults, as found in this study and a previous study [3]. These study results also indicate that one in 5 (over a wide range among states) of those who had a positive COVID test reported long COVID that lasted ≥3 months and caused activity limitations to most. Because common risk factors including obesity and diabetes were shown to increase the risk (odds) of developing long COVID, a typical strategy might be interventions to lower the prevalence of risk factors. But success of such interventions is rare and indeed, risk factors such as obesity [13] and diabetes have been increasing steadily over time. Our finding that long COVID prevalence was reduced 38% (from 9.2% to 5.7%) among adults reporting  $\geq$ 3 vaccine doses vs. those with <3 doses suggests that increasing vaccination rates could be an effective strategy. According to results in Table 1. in order to reduce long COVID rates down to approximately 5.7% by targeting the 5 risk factors would require reducing the number of risk factors to zero! However, due to variation in long COVID rates the 5.7% rate is unlikely to be the same in all states and increasing vaccination rates still appears more feasible than trying to reduce risk factors. Further study of vaccines and COVID for all 50 states is also recommended. Vaccine promotions might need to be carefully tailored to motivate people most likely to resist vaccination [14] and targeted to adults with risk factors, but still seem the best choice.

# Red and blue state comparisons

Some reminders about the red state/blue state data; although the variable defining red and blue states is based on voting in the 2020 Presidential election it should be clear that there are other differences between the states that impact COVID. Adults in red states are significantly more likely to report 4 of the 5 risk factors for long COVID - obesity, diabetes, CVD, and COPD –

compared to those in blue states. Although limited to 29 states, the vaccination data also clearly show that adults in red states are less likely to be vaccinated for COVID. Other study results indicate that number of risk factors and vaccination rates are associated with long COVID rates, so it should not be surprising that red states have higher long COVID rates. These appear to be factors that can be modified by behavior change, with the potential for reducing long COVD rates in red states.

# Comparisons with other studies

Other studies using different sources of data have found different rates of long COVID but this rate of 7.4% from the BRFSS is consistent with the 6% recently reported from another survey with the same definition of long COVID [15] but is much higher than the 1.7% in another study where long COVID was defined as symptoms lasting 2 months [16]. That result is not inconsistent with the wide range of rates this study found among states and could depend on the definition used for long COVID, when results were obtained, and which variants were involved. We found no other studies comparing long COVID with just having a positive test for COVID. The study result for activity limitation among adults with long COVID of 95% is considerably higher than the results of another recent survey where the figure was 26% for "significant" activity limitation [16]. That difference might be due to the adjective "significant" only in the other survey. Further study is needed but these results already suggest a need for support services for people with long COVID.

Vaccine studies have found varying results, depending on the outcome studied, the year, and the variants involved. As one meta-analysis with long COVID as outcome [17] notes, the effectiveness of COVID vaccines on long COVID varies. Two-doses of vaccine lowered risk of COVID compared to no vaccination (OR, 0.64; 95% CI 0.45-0.92) while a single dose did not appear effective. On the other hand, this study suggests that  $\geq$ 3 vaccine doses are needed to be effective, and we found results to be similar for 0, 1, or 2 doses which was our comparison group. A study in Australia [18] also found 3 doses of vaccine were needed to be effective against the Omicron variant of COVID.

Limitations: There are at least five limitations to this study. First, because the BRFSS only surveys households, among the institutions the survey omits are nursing homes and prisons which appeared to have high rates of COVID especially early in the pandemic. Thus, results may underestimate the true rates of COVID and long COVID. Second, results are self-reported and except as noted for COVID are not based on an actual test or diagnosis; the implications of this limitation are unknown. Third, the lack of a measure of hypertension on the survey for 2022 meant that the composite measure of comorbidities lacked a key component (6,7). Fourth, survey results can't distinguish cause and effect so results indicating higher rates of measures such as cognitive disability and frequent activity limitation only indicate an association and could represent risk factors and/or consequences of long COVID. Fifth, vaccination data are only available for 29 states. Lastly, while long COVID was defined as lasting ≥3 months the survey did not determine whether symptoms were temporary or lasted beyond 3 months or whether hospitalizations (or deaths) were involved. The study left many questions about long COVID unanswered and suggesting further investigation.

Strengths: The study also benefitted from using population-based data from all 50 states and DC that were weighted to reflect the population of each state by demographic groups. More importantly, prevalence rates of COVID measures reported for each state showed the wide range of values across states.

#### Conclusion

This study shows that results for just a COVID positive test and long COVID are quite different and each varied widely across states. First, the former compared favorably with both other groups on health and disability measures, while those with long COVID reported consistently poorer health status, disability, and chronic conditions and 95% reported activity limitations. Second, both a positive test and long COVID rates were higher among adults ages 18-64 compared with those 65 and older, contrary to earlier results based on death data. Third, adjusted results showed that more of the risk factors that were found to increase risk of

hospitalization for COVID (obesity, asthma, CVD, diabetes, and COPD)[6,7] also had the

highest AORs for long COVID which affected one-fifth of adults with a positive COVID test.

For the other 80% with a positive test (the just COVID group), younger age and higher income

had the greatest risk, but results suggest this group is in relatively good health. Fourth, regional

and red vs. blue state differences were seen for long COVID but not for just COVID rates, which

may suggest the need to address regions and states differently. These differences may also

suggest realistic goals to set. Fifth, limited data for vaccines show the effectiveness of  $\geq 3$  doses

at reducing rates of COVID and especially long COVID rates. Effectives of vaccines at reducing

long COVID rates appears similar in red and blue states. We conclude that the most effective

way to address COVID now is to concentrate on long COVID with targeted vaccine promotions

for adults with risk factors.

Acknowledgment: This study was partially supported by a cooperative agreement from CDC

12

(#1NU58DP006901) which had no role in the writing of the manuscript.

The authors have no conflicts of interest to disclose.

### References

- [1]. CDC. Long COVID or Post-COVID Conditions. 2023. Available online: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (accessed on 27 January 2024).
- [2]. Pierannunzi C, Hu SS, Balluz L. A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004-2011. BMC Med Res Methodol. 2013;13:49.
- [3]. Nguyen, K.H.; Bao, Y.; Mortazavi, J.; Allen, J.D.; Chocano-Bedoya, P.O.; Corlin, L. Prevalence and Factors Associated with Long COVID Symptoms among U.S. Adults, 2022. Vaccines 2024, 12, 99. https://doi.org/10.3390/vaccines12010099.
- [4]. Adams ML, Grandpre J. Prevalence of COVID-19 and long COVID Results from the 2022 Behavioral Risk Factor Surveillance System, 50 states. MedRxiv preprint doi: https://doi.org/10.1101/2023.09.29.23296352; posted September 29, 2023.
- [5]. Behavioral Risk Factor Surveillance System (BRFSS). Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. 2022 Survey data and documentation. <a href="https://www.cdc.gov/brfss/annual\_data/annual\_2022.html">https://www.cdc.gov/brfss/annual\_data/annual\_2022.html</a>. Accessed September 1, 2023.
- [6]. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458–64.
- [7]. Adams, M. L., Katz, D. L., & Grandpre, J. (2020). Updated Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerging Infectious Diseases, 2020 Sep;26(9):2172-2175. doi: 10.3201/eid2609.202117.

- [8]. Adams, M. L. (2022). Accounting for the Origins and Toll of COVID 19 The key role of Overweight in COVID-19. Am J Health Promot, Feb;36(2), 385–387.
- [9]. Amin MT, Fatema K, Arefin S, Hussain F, Bhowmik DR, Hossain MS. Obesity, a major risk factor for immunity and severe outcomes of COVID-19. Biosci Rep. 2021 Aug 27;41(8):BSR20210979. doi: 10.1042/BSR20210979. PMID: 34350941; PMCID: PMC8380923.
- [10]. Ealey KN, Phillips J, Sung HK. COVID-19 and obesity: fighting two pandemics with intermittent fasting. Trends Endocrinol Metab. 2021 Sep;32(9):706-720. doi: 10.1016/j.tem.2021.06.004. Epub 2021 Jun 25. PMID: 34275726; PMCID: PMC8226104.
- [11]. USA Facts. US COVID-19 cases and deaths by state through date specified (December 31, 2022) <a href="https://usafacts.org/visualizations/coronavirus-covid-19-spread-map">https://usafacts.org/visualizations/coronavirus-covid-19-spread-map</a>. Accessed 12/31/2022.
- [12]. Ahmad FB, Cisewski JA, Xu J, Anderson RN. Provisional Mortality Data United States, 2022. MMWR Morb Mortal Wkly Rep 2023;72:488–492.
  DOI: http://dx.doi.org/10.15585/mmwr.mm7218a3).
- [13]. Pernenkil V, Wyatt T, Akinyemiju T. Trends in smoking and obesity among US adults before, during, and after the great recession and Affordable Care Act roll-out. Prev Med. 2017 Sep; 102:86-92. doi:10.1016/j.ypmed.2017.07.001. Epub 2017 Jul 8.
- [14]. Robertson CT, Bentele K, Meyerson B, et al. Effects of political versus expert messaging on vaccination intentions of Trump voters. PLoS One 16 (2021): e0257988.
- [15]. Ford ND, Slaughter D, Edwards D, et al. Long COVID and Significant Activity Limitation Among Adults, by Age — United States, June 1–13, 2022, to June 7–19, 2023. MMWR Morb Mortal Wkly Rep 2023;72:866–870. DOI: http://dx.doi.org/10.15585/mmwr.mm7232a3

- [16]. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, Green J, Quintana A, Druckman J, Baum MA, Lazer D. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw Open. 2022 Oct 3;5(10):e2238804. doi: 10.1001/jamanetworkopen.2022.38804.
- [17]. Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023 Mar 10;41(11):1783-1790. doi: 10.1016/j.vaccine.2023.02.008. Epub 2023 Feb 8. PMID: 36774332; PMCID: PMC9905096.
- [18]. Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine. 2022 Oct 12;40(43):6288-6294. doi: 10.1016/j.vaccine.2022.09.029. Epub 2022 Sep 21. PMID: 36180375; PMCID: PMC9489983.

Table 1. Long COVID (≥3 months) and just COVID (positive test only), 2022 Behavioral Risk Factor Surveillance System, 50 states plus DC. N= 382,720.

Percents are weighted percentages and n's are unweighted. Comorbidities: obesity, diabetes, cardiovascular disease (CVD), asthma, or chronic obstructive pulmonary disease (COPD).

	Long (	COVID≥3				
Measure>>>>	m	onths	JUST COV	VID (+ test only)		
<b>Population Group</b>		% (95%CI)	n	% (95%CI)	n	N
Total		7.4 (7.3-7.6)	26,305	26.5 (26.2-26.8)	92,091	382,720
Gender						
Males		5.6 (5.4-5.8)	9,514	26.8 (26.4-27.2)	45,019	180,674
Females		9.2 (8.9-9.5)	16,791	26.2 (25.7-26.6)	47,072	202,046
	P value	<.001		0.051		
Age (years)						
18-24		7.3 (6.8-7.8)	1,730	31.8 (30.8-32.9)	7,672	23,185
25-34		8.7 (8.2-9.2)	3,575	31.6 (30.8-32.5)	13,131	40,709
35-44		9.6 (9.0-10.1)	4,744	30.1 (29.4-30.9)	15,031	49,606
45-54		8.9 (8.4-9.3)	5,183	28.1 (27.3-28.9)	14,586	52,618
55-64		7.2 (6.9-7.6)	5,183	24.3 (23.6-25.0)	16,269	70,018
65+		4.3 (4.1-4.6)	5,890	18.3 (17.8-18.8)	24,133	140,241
	P value	<.001		<.001		
Race/ethnicity						
White (non-Hispanic)		7.5 (7.3-7.6)	19,026	26.1 (25.8-26.4)	67,352	285,262
Black		6.5 (6.0-7.1)	1,725	25.8 (24.8-26.7)	6,865	28,750
Hispanic		10.2 (9.0-11.6)	764	25.3 (23.5-27.3)	2,064	8,306
American Indian/AK	Native	9.7 (8.2-11.3)	673	23.5 (21.3-25.8)	1,543	6,004
Asian		4.0 (3.3-4.8)	453	28.5 (26.9-30.2)	3,028	11,993
Other		8.6 (8.0-9.2	2,900	28.7 (27.7-29.7)	8,957	31,527
	P value	<.001		<.001		
Education						
<high school<="" td=""><td></td><td>6.6 (6.0-7.3)</td><td>1,404</td><td>20.7 (19.6-21.8)</td><td>4,317</td><td>21,138</td></high>		6.6 (6.0-7.3)	1,404	20.7 (19.6-21.8)	4,317	21,138
High school		7.1 (6.8-7.5)	6,328	25.8 (25.2-26.4)	20,866	91,757
Some college		8.9 (8.6-9.3)	8,703	27.0 (26.4-27.6)	24,881	104,449
College grad		6.5 (6.3-6.8)	9,789	28.7 (28.3-29.2)	41,727	163,923
	P value	<.001		<.001		
Income						
<\$35K		8.0 (7.7-8.4)	6,441	21.9 (21.3-22.5)	16,257	85,062
\$35-75K		8.1 (7.7-8.5)	6,989	26.5 (25.9-27.1)	22,838	95,904
\$75-\$150		8.1 (7.7-8.5)	6,540	31.0 (30.4-31.6)	25,381	90,506
>\$150K		6.5 (6.0-7.0)	2,605	32.6 (31.7-33.5)	13,077	42,111
Unknown		5.7 (5.4-6.1)	3,730	23.0 (22.3-23.6)	14,537	69,133
	P value	<.001		<.001		

Census Region						
Northeast		6.7 (6.3-7.1)	4,104	27.4 (26.7-28.1)	17,811	72,423
Midwest		7.7 (7.4-8.0)	7,615	25.9 (25.4-26.4)	24,898	102,387
South		7.8 (7.5-8.1)	7,956	26.2 (25.7-26.7)	26,245	108,483
West		7.1 (6.7-7.5)	6,630	26.7 (26.0-27.4)	23,137	99,427
	value	<.001	-,	0.01	-,	,
Red-Blue state status <sup>a</sup>				-		
Blue state		6.6 (6.3-6.9)	9,995	26.8 (26.3-27.2)	41,540	175,820
Red state		8.1 (7.8-8.3)	16,310	26.2 (25.9-26.6)	50,551	206,900
P	value	<.001		0.096		
<b>Employment</b>						
Employed/SE		8.4 (8.1-8.6)	15,874	30.8 (30.4-31.2)	57,422	194,927
Out of work		8.6 (7.8-9.4)	1,279	22.9 (21.6-24.3)	3,095	14,250
Homemaker		7.9 (7.0-9.0)	1,145	21.7 (20.3-23.2)	3,122	14,674
Student		6.7 (5.9-7.6)	687	32.7 (31.0-34.3)	3,156	9,836
Retired		4.2 (3.9-4.5)	4,954	17.9 (17.4-18.4)	20,432	122,253
Unable to work		9.3 (8.6-10.0)	2,176	18.6 (17.6-19.7)	4,132	23,336
P	value	<.001		<.001		
Any kids in household						
Yes		9.6 (9.2-10.0)	9,306	30.7 (30.1-31.2)	29,282	94,408
No		6.4 (6.2-6.6)	16,770	24.4 (24.1-24.8)	61,950	284,753
P	value	<.001		<.001		
4-level gender/kids mea	asure					
Male/no kids		5.0 (4.8-5.2)	6,395	24.9 (24.5-25.4)	31,301	136,222
Female w/kids		11.9 (11.4-12.5)	6,280	30.4 (29.6-31.2)	16,061	51,897
Female/no kids		7.8 (7.5-8.1)	10,375	23.9 (23.4-24.4)	30,649	148,531
Male w/kids		6.8 (6.4-7.3)	3,026	31.0 (30.2-31.9)	13,221	42,511
P	value	<.001		<.001		
Weight status						
Not overweight		5.8 (5.5-6.1)	5,886	25.5 (25.0-26.1)	25,277	111,082
Overweight (BMI >25)		8.3 (8.0-8.5)	18,656	27.2 (26.8-27.6)	61,138	245,845
F	value	<.001		<.001		
<b>Smoking Status</b>						
Non-Smoker		7.5 (7.3-7.7)	22,930	27.4 (27.1-27.8)	83,095	334,139
Current smoker		7.3 (6.8-7.8)	3,222	19.9 (19.2-20.6)	8,385	45,790
P	value	0.433		<.001		
Current E-cigarette us	e					
Yes		10.0 (9.3-10.7)	2,001	31.1 (29.9-32.2)	6,087	20,410
No		7.2 (7.1-7.4)	24,223	26.1 (25.8-26.4)	85,684	360,791
P	value	<.001		<.001		
Depression diagnosis e	ver					
Yes		11.8 (11.4-12.3)	8,661	25.8 (25.2-26.4)	19,138	80,734

No	P value	6.2 (6.0-6.4) <.001	17,460	26.7 (26.3-27.0) 0.016	72,525	299,777
Medicaid	1 varac	<b>\.001</b>		0.010		
No		7.3 (7.2-7.5)	23,215	26.7 (26.4-27.1)	83,597	345,530
Yes		9.4 (8.7-10.1)	2,305	24.7 (23.6-25.8)	5,495	23,232
	P value	<.001	_,,-	<.001	2,172	
Deaf or difficulty he						
Yes	O	8.0 (7.4-8.7)	2,376	20.5 (19.5-21.5)	6,775	35,036
No		7.4 (7.2-7.6)	23,843	27.0 (26.6-27.3)	85,072	346,298
	P value	0.074	,	<.001	,	ŕ
Serious difficulty se	eing					
Yes	J	8.8 (8.1-9.6)	1,870	21.5 (20.2-22.8)	3,920	20,469
No		7.3 (7.2-7.5)	24,344	26.8 (26.5-27.1)	87,964	361,081
	P value	<.001		<.001		
Difficulty walking						
Yes		9.4 (9.0-10.0)	5,288	19.0 (18.3-19.7)	10,702	61,053
No		7.1 (6.9-7.3)	20,919	27.7 (27.4-28.0)	81,164	320,335
	P value	<.001		<.001		
Difficulty dressing/b	oathing					
Yes		10.4 (9.4-11.4)	1,504	18.5 (17.1-19.9)	2,459	14,955
No		7.3 (7.1-7.5)	24,756	26.8 (26.5-27.1)	89,533	367,179
	P value	<.001		<.001		
Difficulty doing erra	ands alone					
Yes		10.5 (9.8-11.3)	2,998	19.3 (18.4-20.3)	5,024	29,165
No		7.2 (7.0-7.3)	23,217	27.1 (26.8-27.4)	86,900	352,353
	P value	<.001		<.001		
Cognitive difficultie	S					
Yes		12.1 (11.5-12.7)	5,431	23.5 (22.7-24.3)	9,669	45,149
No		6.7 (6.5-6.9)	20,649	27.0 (26.7-27.3)	81,930	335,041
	P value	<.001		<.001		
Cardiovascular dise	ease	7.0./7.2.0.2	2.250	20.2 (10.4.21.2)	0.655	45.520
Yes		7.8 (7.3-8.3)	3,359	20.3 (19.4-21.2)	8,657	45,538
No	D 1	7.4 (7.2-7.6)	22,642	27.2 (26.9-27.5)	82,653	332,977
Diahataa	P value	0.102		<.001		
<b>Diabetes</b>		01(7606)	4.005	22 4 (22 6 24 2)	11 242	52.540
Yes No		8.1 (7.6-8.6) 7.3 (7.2-7.5)	4,095	23.4 (22.6-24.3) 26.9 (26.6-27.2)	11,343 80,613	52,540
INO	P value	<.001	22,165	<.001	80,013	329,435
Current asthma	r value	<.001		<.001		
Yes		13.1 (12.4-13.8)	4,824	26.4 (25.5-27.3)	9,321	39,517
No		6.8 (6.6-7.0)	21,165	26.5 (26.2-26.8)	82,103	339,997
110	P value	<.001	21,103	0.824	02,103	557,331
COPD	1 value	<b>\.001</b>		0.024		

Yes		11.0 (10.2-11.7)	3,081	19.2 (18.3-20.1)	5,576	31,046
No		7.2 (7.0-7.3)	23,067	27.0 (26.7-27.3)	86,211	349,968
	P value	<.001		<.001		
Obese						
Yes		9.8 (9.5-10.2)	10,912	27.4 (26.9-27.9)	30,554	120,174
No		6.3 (6.1-6.5)	13,630	26.3 (25.9-26.7)	55,861	236,753
	P value	<.001		<.001		
Any of 5 comorbid	ities					
No		5.7 (5.5-6.0)	8,795	27.7 (27.2-28.1)	42,160	168,518
Yes		9.2 (8.9-9.5)	15,054	25.9 (25.4-26.3)	42,621	180,268
	P value	<.001		<.001		
Number of co-mor	bidities					
0		5.7 (5.5-6.0)	8,795	27.7 (27.2-28.1)	42,160	168,518
1		8.4 (8.0-8.7)	8,551	27.0 (26.4-27.5)	28,365	115,088
2		10.4 (9.8-11.0)	4,285	24.2 (23.4-25.1)	10,296	45,479
3 or more		12.2 (11.2-13.0)	2,218	22.0 (20.8-23.2)	3,960	19,701
	P value	<.001		<.001		
<b>Health Status</b>						
Fair or poor		10.5 (10.0-10.9)	6,844	22.0 (21.3-22.7)	13,317	67,926
Good or better		6.8 (6.6-7.0)	19,395	27.5 (27.1-27.8)	78,605	313,854
	P value	<.001		<.001		
FMD						
Yes		12.0 (11.4-12.5)	6,132	25.8 (25.1-26.6)	12,056	51,964
No		6.6 (6.4-6.8)	19,661	26.7 (26.4-27.0)	78,535	323,388
	P value	<.001		0.041		
FAL						
Yes		12.2 (11.5-12.9)	4,282	22.8 (21.9-23.8)	7,451	36,615
No		6.9 (6.7-7.1)	21,657	27.0 (26.6-27.3)	83,623	340,900
	P value	<.001		<.001		
Weight status						
Underweight		6.4 (5.0-8.1)	323	22.0 (19.8-24.3)	1,154	6,035
Healthy weight		5.8 (5.5-6.0)	5,563	25.7 (25.2-26.3)	24,123	105,047
Overweight only		6.8 (6.5-7.1)	7,744	27.0 (26.5-27.5)	30,584	125,671
Obese (30-34.9)		8.7 (8.3-9.2)	5,605	27.0 (26.3-27.7)	17,739	70,137
Obese 2 (35+)		11.3 (10.7-11.9)	5,307	27.9 (27.1-28.7)	12,815	50,037
	P value	<.001		<.001		
HIV risk <sup>b</sup>						
No		7.2 (7.1-7.4)	24,584	26.1 (25.8-26.4)	86,483	364,738
Yes		10.6 (9.7-11.5)	1,649	32.2 (30.8-33.5)	5,288	16,521
	P value	<.001		<.001		
State						
AL		10.6 (9.3-12.1)	372	27.5 (25.6-29.5)	1,043	4,158
AK		7.5 (6.5-8.6)	345	29.8 (28.0-31.6)	1,406	5,199

AZ	8.2 (7.3-9.2)	638	27.9 (26.3-29.5)	2,069	8,788
AR	8.2 (7.2-9.3)	337	26.3 (24.6-28.1)	1,023	4,450
CA	6.7 (5.9-7.5)	574	28.7 (27.4-30.1)	2,521	9,132
CO	7.3 (6.6-8.0)	583	24.5 (23.4-25.6)	2,007	8,306
CT	6.3 (5.6-7.1)	519	30.8 (29.2-32.4)	2,351	8,098
DE	6.7 (5.5-8.2)	210	27.4 (25.3-29.6)	848	3,419
DC	4.4 (3.4-5.7)	93	24.8 (22.6-27.0)	577	2,783
FL	6.9 (6.0-7.9)	805	25.1 (23.4-26.8)	2,622	11,268
GA	7.7 (6.8-8.6)	567	26.4 (24.9-27.9)	1,924	7,790
HI	4.2 (3.5-4.8)	274	24.9 (23.5-26.4)	1,566	7,068
ID	8.8 (7.9-9.7)	511	23.8 (22.5-25.2)	1,341	5,958
IL	7.2 (6.3-8.3)	261	26.6 (24.8-28.5)	947	3,619
IN	7.9 (7.2-8.6)	639	25.7 (24.5-26.9)	2,060	8,783
IA	7.7 (7.0-8.5)	597	25.3 (24.1-26.6)	1,957	8,213
KS	8.2 (7.4-8.9)	755	26.4 (25.2-27.7)	2,390	10,159
KY	8.0 (6.8-9.3)	303	27.9 (25.9-30.0)	956	3,785
LA	9.1 (8.1-10.3)	432	29.1 (27.4-30.8)	1,364	4,913
ME	5.3 (4.7-6.0)	472	21.1 (20.0-22.3)	1,901	10,115
MD	5.2 (4.6-5.9)	678	25.6 (24.4-26.9)	3,196	13,785
MA	5.8 (5.2-6.5)	584	26.8 (25.6-28.1)	2,654	10,072
MI	7.4 (6.7-8.2)	533	24.1 (22.9-25.3)	1,857	8,546
MN	7.2 (6.7-7.8)	960	26.5 (25.6-27.5)	3,768	14,499
MS	9.5 (8.4-10.7)	375	30.9 (29.0-32.8)	1,206	3,922
MO	8.3 (7.5-9.2)	560	25.3 (24.0-26.8)	1,666	6,967
MT	10.2 (9.2-11.2)	581	25.2 (23.8-26.5)	1,535	6,597
NE	8.1 (7.2-9.1)	514	25.2 (23.7-26.7)	1,530	6,855
NV	8.5 (7.1-10.3)	203	27.5 (25.1-30.1)	702	2,743
NH	5.7 (4.9-6.7)	253	24.9 (23.2-26.6)	1,088	5,806
NJ	7.1 (6.3-8.0)	438	26.4 (25.0-27.9)	1,758	6,547
NM	8.0 (6.8-9.3)	307	26.3 (24.4-28.4)	949	4,356
NY	6.6 (6.0-7.2)	945	28.9 (27.9-30.0)	4,092	14,978
NC	7.0 (6.1-8.0)	313	24.5 (22.8-26.3)	1,011	4,183
ND	10.0 (8.8-11.3)	335	29.1 (27.4-30.9)	1,033	3,881
ОН	8.3 (7.7-9.0)	1,194	26.0 (24.9-27.1)	3,421	13,990
OK	10.2 (9.3-11.2)	525	27.1 (25.7-28.6)	1,321	5,187
OR	5.5 (4.8-6.3)	271	19.2 (17.9-20.5)	1,022	5,423
PA	7.5 (6.4-8.8)	308	26.4 (24.5-28.5)	1,129	4,236
RI	5.8 (4.9-6.8)	272	27.9 (26.1-29.8)	1,258	4,928
SC	7.4 (6.7-8.2)	582	26.7 (25.3-28.1)	1,954	8,423
SD	8.6 (6.2-11.7)	618	26.5 (23.5-29.7)	1,839	7,164
TN	10.2 (9.1-11.5)	458	27.4 (25.7-29.2)	1,189	4,608
TX	7.9 (7.1-8.8)	904	26.3 (24.9-27.7)	2,964	12,135
UT	9.6 (8.8-10.5)	784	27.5 (26.3-28.8)	2,320	8,771
- <del>-</del>	×.0 (0.0 10.0)		(= 3.2 <b>2</b> 0.0)	_,====	-,

VT		4.7 (4.0-5.5)	313	23.7 (22.3-25.2)	1,580	7,643
VA		6.8 (6.1-7.6)	547	24.5 (23.2-25.8)	1,921	9,067
WA		5.9 (5.6-6.4)	1,238	22.8 (22.1-23.6)	4,834	23,433
WV		11.1 (10.0-12.3)	455	26.8 (25.2-28.4)	1,126	4,607
WI		7.0 (6.4-7.7)	649	27.2 (25.9-28.4)	2,430	9,711
WY		10.0 (8.8-11.4)	321	26.7 (24.9-28.7)	865	3,653
Total		7.4 (7.3-7.6)	26,305	26.5 (26.2-26.8)	92,091	382,720
	P value	<.001		<.001		

Abbreviations: FMD: Frequent (≥14 days) poor mental health in past 30 days; FAL: Frequent activity limitation; COPD: Chronic obstructive pulmonary disease;

<sup>&</sup>lt;sup>a</sup>Blue and red states assigned by voting in 2020 Presidential election.

<sup>&</sup>lt;sup>b</sup>HIV risk: Any in past year: Injected a non-prescribed drug; treated for a sexually transmitted disease; exchanged money or drugs for sex.

Table 2. Weighted results of logistic regression, controlled for the measures listed, 2022 Behavioral Risk Factor Surveillance System, 50 states & DC, N=329,521. COVID risks=obesity, diabetes, cardiovascular disease, chronic obstructive pulmonary disease, asthma.

Outcome>>>	Long COVID≥3	months	Just COVID + test		
Group	AOR (95% CI)	P value	AOR (95% CI)	P value	
Females w/kids v M, no kids	2.21 (2.03-2.40)	<.001	1.12 (1.06-1.18)	<.001	
Females no kids v M no kids	1.77 (1.65-1.89)	<.001	1.01 (0.97-1.05)	<.001	
Males w/kids v M no kids	1.19 (1.08-1.31)	<.001	1.11 (1.05-1.17)	<.001	
55-64 years v 65+	1.77 (1.62-1.94)	<.001	1.35 (1.28-1.43)	<.001	
45-54 years v 65+	2.23 (2.02-2.46)	<.001	1.55 (1.46-1.64)	<.001	
35-44 years v 65+	2.37 (2.13-2.64)	<.001	1.70 (1.60-1.81)	<.001	
25-34 years v 65+	2.28 (2.06-2.53)	<.001	1.91 (1.80-2.02)	<.001	
18-24 years v 65+	2.07 (1.84-2.34)	<.001	2.01 (1.88-2.15)	<.001	
Black v non-Hispanic white	0.73 (0.67-0.80)	<.001	0.97 (0.92-1.03)	0.289	
Hispanic v non-Hispanic white	1.21 (1.04-1.41)	0.016	0.90 (0.82-1.00)	0.054	
Am. Indian v non-Hispanic white	1.16 (0.94-1.42)	0.158	0.91 (0.80-1.04)	0.155	
Asian v. non-Hispanic white	0.52 (0.42-0.65)	<.001	0.96 (0.88-1.06)	0.445	
Other v. non-Hispanic white	1.03 (0.94-1.13)	0.522	1.10 (1.03-1.16)	0.002	
\$25-<\$50K v < \$25K	1.10 (0.99-1.22)	0.067	1.26 (1.18-1.35)	<.001	
\$50-<\$75K v < \$25K	1.18 (1.06-1.32)	0.002	1.44 (1.34-1.54)	<.001	
\$75K-<\$100K v < \$25K	1.23 (1.09-1.38)	0.001	1.55 (1.44-1.67)	<.001	
\$100K+ v <\$25K	1.04 (0.93-1.16)	0.498	1.75 (1.64-1.88)	<.001	
Unknown v <\$25K income	0.86 (0.77-0.97)	0.012	1.15 (1.07-1.23)	<.001	
Annual flu shot v no	0.86 (0.81-0.91)	<.001	0.97 (0.93-1.00)	0.075	
Smoker v non-smoker	0.77 (0.70-0.83)	<.001	0.67 (0.64-0.71)	<.001	
1 COVID risk v 0	1.52 (1.42-1.62)	<.001	1.04 (1.00-1.08)	0.043	
2 COVID risk v 0	2.25 (2.07-2.44)	<.001	1.06 (1.00-1.12)	0.033	
3+COVID risk v 0	2.94 (2.64-3.27)	<.001	1.11 (1.03-1.20)	0.009	
HIV risk <sup>a</sup> v no	1.32 (1.19-1.47)	<.001	1.17 (1.09-1.25)	<.001	
E-cigarettes v no	1.23 (1.12-1.36)	<.001	1.13 (1.06-1.21)	<.001	
Red states v Blue states <sup>b</sup>	1.15 (1.09-1.22)	<.001	1.00 (0.96-1.03)	0.891	
COVID risks if entered separately					
Obesity	1.41 (1.33-1.50)	<.001	1.07 (1.04-1.11)	<.001	
Diabetes	1.22 (1.12-1.33)	<.001	1.08 (1.02-1.14)	0.008	
Cardiovascular disease	1.30 (1.19-1.42)	<.001	0.99 (0.93-1.05)	0.666	
COPD	1.56 (1.40-1.73)	<.001	0.89 (0.83-0.96)	0.002	
Asthma	1.63 (1.51-1.77)	<.001	1.02 (0.96-1.08)	0.488	

Abbreviations: AOR: adjusted odds ratio; COPD: chronic obstructive pulmonary disease;

<sup>&</sup>lt;sup>a</sup>HIV risk: Any in past year: Injected a non-prescribed drug; treated for a sexually transmitted disease; exchanged money or drugs for sex.

<sup>&</sup>lt;sup>b</sup> Assigned by voting in 2020 Presidential election.

Table 3. Direct comparison of measures of long COVID<sup>a</sup>, just a positive test<sup>b</sup>, and neither, 2022 Behavioral Risk Factor Surveillance System, all age 18+, N=382,720.

	ure among these adults>	Long COVID <sup>a</sup>	+ test <sup>b</sup>	Neither	Total	P value
Health conditi N=	ons	26,305	92,091	264,324	382,720	
Any CVD		9.8	7.1	10.2	9.3	<.001
·	95% CIs	9.2-10.5	6.8-7.5	9.9-10.4	9.2-9.5	
Arthritis		33.2	23.3	28.2	27.3	<.001
	95% CIs	32.1-34.3	22.8-23.9	27.9-28.6	27.0-27.6	
Diabetes		13.2	10.7	12.5	12.1	<.001
Diabetes	95% CIs	12.4-14.0	10.7	12.3	11.9-12.3	<.001
CORD		10.1	<b>7</b> 0	7.0	6.0	001
COPD	95% CIs	10.1 9.4-10.9	<b>5.0</b> 4.7-5.2	7.2 7.1-7.4	6.9 6.7-7.0	<.001
	93% CIS	9.4-10.9	4.7-3.2	7.1-7.4	0.7-7.0	
Asthma (currer	nt)	17.6	9.9	9.1	10.0	<.001
	95% CIs	16.7-18.5	9.5-10.3	8.9-9.3	9.8-10.1	
Cancer other th	an skin includes					
melanoma		7.9	7.0	9.0	8.4	<.001
	95% CIs	7.3-8.5	6.7-7.3	8.8-9.2	8.2-8.6	
Disability and	related issues					
Deaf or difficul	lty hearing	7.6	5.5	7.6	7.1	<.001
	95% CIs	7.0-8.3	5.2-5.8	7.4-7.9	6.9-7.2	
Blind or seriou	s problems seeing	6.7	4.5	5.9	5.6	<.001
	95% CIs	6.1-7.2	4.2-4.9	5.7-6.1	5.4-5.8	
Difficulty walk	ing/climbing stairs	17.5	9.9	14.9	13.7	<.001
- Difficulty want	95% CIs	16.6-18.4	9.5-10.3	14.6-15.2	13.5-14.0	<.001
Difficulty bathi	in a /dua a sin a	5.3	26	4.1	2.0	۰ 001
Difficulty batti	95% CIs	4.8-5.8	<b>2.6</b> 2.4-2.9	4.1 3.9-4.2	3.8 3.6-3.9	<.001
	73 /0 CIS	4.0-3.0	2.4-2.7	3.7-4.2	3.0-3.7	
Difficulty doin	g errands alone	11.2	5.8	8.4	7.9	<.001
	95% CIs	10.5-12.1	5.5-6.1	8.2-8.7	7.7-8.1	
Difficulty with	memory, concentrating	21.9	11.9	13.1	13.5	<.001
J 12	95% CIs	20.9-22.9	11.5-12.4	12.8-13.4	13.2-13.7	-

Health status & related					
Fair or poor health status	25.2	14.9	18.3	17.9	<.001
95% CIs	24.2-26.3	14.4-15.4	18.0-18.7	17.7-18.2	
Frequent mental distress (FMD)	25.6	15.5	15.0	15.9	<.001
95% CIs	24.6-26.7	15.0-16.0	14.7-15.3	15.7-16.2	
Frequent physical distress (FPD)	20.7	10.8	12.5	12.7	<.001
95% CIs	19.6-21.7	10.4-11.3	12.2-12.8	12.4-12.9	
Frequent activity limitation (FAL)	16.2	8.5	9.7	9.9	<.001
95% CIs	15.3-17.1	8.1-8.9	9.5-10.0	9.7-10.1	
Unable to work	8.1	4.6	7.1	6.5	<.001
95% CIs	7.5-8.8	4.3-4.9	6.9-7.4	6.4-6.7	
Health behaviors and risk factors					
All overweight (BMI>25)	74.9	69.1	66.3	67.7	<.001
95% CIs	73.9-76.0	68.4-69.7	65.9-66.7	67.4-68.0	
Obese (BMI=30+)	44.1	34.5	32.0	33.6	<.001
95% CIs	42.9-45.4	33.9-35.2	31.6-32.4	33.3-33.9	
Current smoking	12.3	9.5	13.9	12.6	<.001
95% CIs	11.6-13.1	9.1-9.9	13.6-14.2	12.4-12.9	
**	<b>7.</b> 1				0.006
Heavy drinking	7.1	6.9	6.4	6.6	0.006
95% CIs	6.6-7.8	6.5-7.2	6.2-6.6	6.4-6.7	
<b>F</b> : "	10.0	0.7		7.4	. 001
E-cigarettes current	10.0	8.7	6.6	7.4	<.001
95% CIs	9.3-10.7	8.4-9.1	6.4-6.9	7.3-7.6	
Any 5 co-morbidities/risk factors <sup>c</sup>	61.0	47.7	48.8	49.4	<.001
95% CIs	59.7-62.2	47.0-48.4	48.3-49.2	49.0-49.7	
	• • •	•0.6	24.7	22.7	001
No leisure time activity (sedentary)	24.9	20.6	24.5	23.5	<.001
95% CIs	23.9-26.0	20.0-21.1	24.1-24.8	23.2-23.8	
D	22.0	20.7	20.0	21.2	001
Depression diagnosis	33.9	20.7	20.0	21.2	<.001
95% CIs	32.7-35.0	20.2-21.2	19.7-20.4	21.0-21.5	
TT 1/1					
Health access measures	0.2		0.0	0.2	. 001
No health care coverage	8.3	6.6	9.0	8.3	<.001

	95% CIs	7.6-9.1	6.2-7.0	8.7-9.3	8.1-8.5	
Medicaid cove	erage	10.6	7.9	8.5	8.5	<.001
	95% CIs	9.9-11.5	7.5-8.3	8.3-8.8	8.3-8.7	
Unable to see	MD because of cost	19.4	9.9	10.6	11.0	<.001
	95% CIs	18.3-20.4	9.5-10.3	10.3-10.8	10.8-11.3	
Other						
Females		63.4	50.6	50.0	51.1	<.001
	95% CIs	62.3-64.6	49.9-51.2	49.5-50.4	50.8-51.5	
Ages 18-64		86.3	83.8	72.4	76.5	<.001
	95% CIs	85.5-87.1	83.3-84.2	72.1-72.7	76.2-76.7	
≥3 vaccines <sup>d</sup>		35.6	42.7	50.3	47.1	<.001
	95% CIs	33.9-37.3	41.7-43.6	49.6-50.9	46.6-47.6	

<sup>&</sup>lt;sup>a</sup> Long COVID: symptoms lasting ≥3 months

<sup>&</sup>lt;sup>b</sup> Just a positive COVID test, not long COVID

<sup>&</sup>lt;sup>c</sup> Obesity, cardiovascular disease, chronic obstructive pulmonary disease, diabetes or asthma.

<sup>&</sup>lt;sup>d</sup> 29 states that asked optional vaccine questions; AR, CT, DE, GA, HI, ID, IL, IA, KS, LA, ME, MD, MA, MT, NE, NH, NJ, NM, NY, NC, ND, OK, RI, SC, TN, TX, WV, WI, and WY. Figures in bold represent lowest among the 4 groups,